Latest Denosumab Stories
This Approval Provides a New Treatment Option for a Patient Population With High Unmet Medical Need THOUSAND OAKS, Calif., Dec.
Plans to Payout Approximately 60 Percent of Adjusted Net Income on Average to Shareholders Through 2018 NEW YORK, Oct.
Data Presented at the American Society of Bone and Mineral Research 2014 Annual Meeting THOUSAND OAKS, Calif., Sept.
Romosozumab Currently in Phase 3 Clinical Development, Pivotal Data Expected in 2016 THOUSAND OAKS, Calif. and BRUSSELS, Sept.
Data Include Eight Year Analyses of Bone Mineral Density Results for Prolia® (Denosumab) and Further Evidence for Significant Bone-Building With Romosozumab THOUSAND OAKS, Calif., Sept.
New Data Reinforces Commitment to Personalized Medicine and Highlights Advances in Immunotherapy Platform THOUSAND OAKS, Calif.
A study comparing the efficacy and tolerability of two popular osteoporosis drugs, denosumab and zoledronic acid, found that denosumab had a significantly greater effect on increasing spine bone mineral density and zoledronic acid caused more flulike symptoms.
Transparency Market Research published new "Global Osteoporosis Drug Market- China Industry Analysis, Size, Share, Growth, Trends and Forecast, 2010 - 2015" market research report to